Surgery in patients with bleeding disorders: Expensive treatment for a small group of patients;Kirurgi ved alvorlig blødersykdom - Kostbar behandling til en liten pasientgruppe

Tidsskrift for den Norske Laegeforening

Volumn 125, Issue 7, 2005, Pages 883-885

  Mishra, Vinod ^a   Paus, Albert C ^a   Tjønnfjord, Geir E ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BLOOD CLOTTING FACTOR CONCENTRATE; HAEMATE; OCTANATE; OCTANINE F; OCTAPLEX F; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; COAGULATING AGENT; HEMOSTATIC AGENT;

ARTICLE; BLEEDING DISORDER; COST BENEFIT ANALYSIS; DISEASE SEVERITY; ELECTIVE SURGERY; HEMOPHILIA A; HEMOPHILIA B; HUMAN; NORWAY; OUTCOMES RESEARCH; PEROPERATIVE CARE; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE TREATMENT; SAFETY; UNIVERSITY HOSPITAL; VON WILLEBRAND DISEASE; BLEEDING; BLOOD CLOTTING DISORDER; DRUG COST; ECONOMICS; PREMEDICATION; PREOPERATIVE CARE; RISK FACTOR; SURGERY;

BLOOD COAGULATION DISORDERS; BLOOD LOSS, SURGICAL; COAGULANTS; COAGULATION PROTEIN DISORDERS; DRUG COSTS; HEMOPHILIA A; HEMOPHILIA B; HEMOSTATICS; HUMANS; INTRAOPERATIVE CARE; POSTOPERATIVE CARE; PREMEDICATION; PREOPERATIVE CARE; RISK FACTORS; SURGICAL PROCEDURES, OPERATIVE;

EID: 16844372251     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69: 454-9.
2. Werner EJ, Broxson EH, Tucker EL et al. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr 1993; 123: 893-8.
3. Ekert H, Brewin T, Boey W et al. Cost-utility analysis of recombinant factor Vila (NovoSeven) in six children with long-standing inhibitors to factor VIII or IX. Haemophilia 2001; 7: 279-85.
4. Aledort LM. Economic aspects of haemophilia care. Haemophilia 1999; 5: 373.
5. Paisley S, Wight J, Currie E et al. The management of inhibitors in haemophilia. An introduction and systematic review of current practice. Haemophilia 2003; 9; 405-17.
6. Mishra V, Tjonnfjord GE, Paus AC et al. Orthopaedic surgery in severe bleeding disorders: a low-volume, high-cost procedure. Haemophilia 2002; 8: 809-14.
7. Bohn RL, Colowick AB, Avorn J. Probabilities, costs, and outcomes: methodological issues in modelling haemophilia treatment. Haemophilia 1999; 5: 374-7.
8. Miners AH, Sabin CA, Tolley KH et al. Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease. J Intern Med 1998; 244: 515-22.
9. Kelley SS, Lachiewicz PF, Gilbert MS et al. Hip arthroplasty in hemophilic arthropathy. J Bone Joint Surg Am 1995; 77: 828-34.
10. Szucs TD, Offner A, Kroner B et al. Resource utilisation in haemophiliacs treated in Europe: results from the European Study on Socioeconomic Aspects of Haemophilia Care. The European Socioeconomic Study Group. Haemophilia 1998; 4: 498-501.
11. Galanaud JP, Pelletier-Fleury N, Logerot-Lebrun H et al. Determinants of drug costs in hopitalised patients with haemophilia: impact of recombinant activated factor VII. Pharmacoeconomics 2003; 21: 699-707.
12. Lee C, Sabin C, Miners A. High cost, low volume care: the case of haemophilia. BMJ 1997; 315: 962-3.
13. Teigland JC, Tjonnfjord GE, Evensen SA et al. Knee arthroplasty in hemophilia. 5-12 year follow-up of 15 patients. Acta Orthop Scand 1993; 64: 153-6.
14. Teigland JC, Tjonnfjord GE, Evensen SA et al. Synovectomy for haemophilia arthropathy; 6-21 years of follow-up in 16 patients. J Intern Med 1994; 235: 239-43.